RAD51-INHIBITOREN

European patent · EP3681884 · In force

Register entry

Publication number
EP3681884
Application number
EP18782257
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Sep 11, 2018
Published
Jul 22, 2020
Granted
Jun 1, 2022
Protection ends at the latest
Sep 10, 2038
Next annual fee due
Sep 30, 2026
IPC classes
C07D 417/04 (2006.01)
C07D 417/14 (2006.01)
C07D 277/42 (2006.01)
C07D 277/28 (2006.01)
C07D 417/12 (2006.01)
A61P 25/28 (2006.01)
A61P 35/00 (2006.01)
A61P 37/00 (2006.01)
A61K 31/427 (2006.01)
Priority
US 201762556763 P 11.09.2017
US 201862711959 P 30.07.2018
PCT application
PCT/US2018/050391 11.09.2018
PCT publication
WO2019/051465 14.03.2019
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Oct 1, 2025

    Change

    Published in Swissreg on 01.10.2025

  2. Oct 3, 2024

    Change

    Published in Swissreg on 03.10.2024

  3. Oct 1, 2023

    Change

    Published in Swissreg on 01.10.2023

  4. Apr 12, 2023

    Change

    Published in Swissreg on 12.04.2023

  5. Oct 1, 2022

    Change

    Published in Swissreg on 01.10.2022

  6. Jun 1, 2022

    Granted

    Published in Swissreg on 01.06.2022

Parties

Holder

Cyteir Therapeutics, Inc.

128 Spring Street, Building A, Suite 510, Lexington, MA 02421, US

Inventor

CASTRO, Alfredo C.

Woburn MA 01801, US

MCCOMAS, Casey Cameron

Phoenixville PA 19460, US

VACCA, Joseph

Telford PA 18969, US

MACLAY, Tyler

Cambridge MA 02138, US

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.